Larson-Green Julie 4

What Happened

• Julie Larson‑Green, a Health Catalyst (HCAT) director, was granted 12,710 restricted stock units (RSUs) that were reported as acquired at $0.00 on June 1, 2026. Per the filing footnote, these RSUs represent a contingent right to one share each and 100% of the award vested on June 1, 2026 under the company’s 2019 Plan and the Non‑Employee Director Compensation Policy.
• This was an equity award/vesting event (code A), not an open‑market purchase or sale. The $0.00 acquisition price indicates a compensatory grant/vesting rather than a cash purchase.

Key Details

• Transaction date: June 1, 2026; Report filed: June 3, 2026 (Form 4 accession 0001796545-26-000002).
• Shares/units: 12,710 RSUs granted and vested; acquisition price reported $0.00.
• Shares owned after transaction: not specified in the provided summary of the filing.
• Footnote: Confirms RSUs granted under the 2019 Stock Option and Incentive Plan and that 100% vested on June 1, 2026 per the Non‑Employee Director Compensation Policy.
• Timeliness: Filing was submitted on June 3, 2026—within the typical two‑business‑day Form 4 reporting window (not indicated as late).

Context

• RSUs are a form of compensation: each unit entitles the holder to one share upon settlement. Vesting is a routine director compensation event and does not itself signal a buy or sell decision in the open market.
• Because this was an award/vesting (not a market purchase or sale), it’s primarily a compensation disclosure rather than an insider investment signal for retail investors.